ERNA (Ernexa Therapeutics) Short Interest


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $7.26
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ERNA vs KPRX, PHGE, BRTX: Short Interest Comparison

For the Biotechnology subindustry, Ernexa Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ernexa Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Ernexa Therapeutics's Short Interest falls into.


ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price